John C. Byrd, MD, on Long-Term Follow-up of Acalabrutinib Treatment in CLL/SLL

Posted: Wednesday, July 8, 2020

John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center, discusses the significance of the mature data reported in a phase II study supporting favorable results with acalabrutinib in phase III trials, the challenge of long-term side effects, and how to manage them.